BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34344201)

  • 21. Pembrolizumab induced toxic epidermal necrolysis.
    Kumar R; Bhandari S
    Curr Probl Cancer; 2020 Apr; 44(2):100478. PubMed ID: 31122669
    [No Abstract]   [Full Text] [Related]  

  • 22. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
    Boruah PK; Bolesta S; Shetty SM
    Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report.
    Han C; Ma JA; Zhang Y; Jiang Y; Hu C; Wu Y
    Mol Clin Oncol; 2020 Jul; 13(1):38-42. PubMed ID: 32499912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
    Cesarini M; Angelucci E; Foglietta T; Vernia P
    J Crohns Colitis; 2011 Dec; 5(6):619-22. PubMed ID: 22115384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stevens-Johnson Syndrome Induced by Pembrolizumab in a Lung Cancer Patient.
    Haratake N; Tagawa T; Hirai F; Toyokawa G; Miyazaki R; Maehara Y
    J Thorac Oncol; 2018 Nov; 13(11):1798-1799. PubMed ID: 29885481
    [No Abstract]   [Full Text] [Related]  

  • 26. Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report.
    Cao J; Li Q; Zhi X; Yang F; Zhu W; Zhou T; Hou X; Chen D
    Transl Cancer Res; 2021 Aug; 10(8):3870-3876. PubMed ID: 35116686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stevens-Johnson syndrome and toxic epidermal necrolysis at the University Hospital of the West Indies, Jamaica.
    East-Innis AD; Thompson DS
    West Indian Med J; 2013 Sep; 62(7):589-92. PubMed ID: 24831894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.
    Xu C; Pan L; Zhang Y; Zhang J; Sun Q; Fang W
    Int J Clin Pract; 2021 Aug; 75(8):e14273. PubMed ID: 33908133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Case of Stevens-Johnson Syndrome in Recurrent Late-Stage Ovarian Cancer Patient after Management of Chronic Pain with Elastomeric Pump.
    Cokan A; Gavrić Lovrec V; Takač I
    Curr Oncol; 2021 Aug; 28(4):2928-2932. PubMed ID: 34436022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case Report: ICIs-induced Guillain-Barré syndrome recovered from mycophenolate mofetil.
    Ding M; Deng C; Liu X; Jiang S; Gao Y; Fan D; Zhou Y; He J; Liu C
    Front Immunol; 2023; 14():1132692. PubMed ID: 37223099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pembrolizumab-induced toxic epidermal necrolysis: A rare cause of severe adverse drug reaction.
    Neema S; Sathu S; Vasudevan B; Shreshta S; Bhatt S; K L
    Indian J Dermatol Venereol Leprol; 2023; 89(4):589-591. PubMed ID: 37067146
    [No Abstract]   [Full Text] [Related]  

  • 32. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum.
    Power WJ; Ghoraishi M; Merayo-Lloves J; Neves RA; Foster CS
    Ophthalmology; 1995 Nov; 102(11):1669-76. PubMed ID: 9098260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stevens-Johnson syndrome after erythromycin therapy while deployed at sea.
    Williams DA
    Mil Med; 2000 Aug; 165(8):636-7. PubMed ID: 10957862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Lamotrigine and its relationship with Stevens-Johnson syndrome and toxic epidermal necrolysis].
    Velázquez-Cárcamo EA; Rodríguez-Chávez Y; Méndez-Flores S; Domínguez-Cherit J
    Rev Med Inst Mex Seguro Soc; 2020 Apr; 58(2):202-205. PubMed ID: 34101565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxic epidermal necrolysis syndrome induced by tigecycline: a case report.
    Yang J; Wu F; Luo D; Li M; Gou X; Xi J; Zhu H
    J Int Med Res; 2020 May; 48(5):300060520922416. PubMed ID: 32400243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
    Ririe MR; Blaylock RC; Morris SE; Jung JY
    J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective.
    Gupta LK; Martin AM; Agarwal N; D'Souza P; Das S; Kumar R; Pande S; Das NK; Kumaresan M; Kumar P; Garg A; Singh S
    Indian J Dermatol Venereol Leprol; 2016; 82(6):603-625. PubMed ID: 27716721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme.
    Bastuji-Garin S; Rzany B; Stern RS; Shear NH; Naldi L; Roujeau JC
    Arch Dermatol; 1993 Jan; 129(1):92-6. PubMed ID: 8420497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; van den Berg B; Doets AY; Leonhard SE; Verboon C; Huizinga R; Drenthen J; Arends S; Budde IK; Kleyweg RP; Kuitwaard K; van der Meulen MFG; Samijn JPA; Vermeij FH; Kuks JBM; van Dijk GW; Wirtz PW; Eftimov F; van der Kooi AJ; Garssen MPJ; Gijsbers CJ; de Rijk MC; Visser LH; Blom RJ; Linssen WHJP; van der Kooi EL; Verschuuren JJGM; van Koningsveld R; Dieks RJG; Gilhuis HJ; Jellema K; van der Ree TC; Bienfait HME; Faber CG; Lovenich H; van Engelen BGM; Groen RJ; Merkies ISJ; van Oosten BW; van der Pol WL; van der Meulen WDM; Badrising UA; Stevens M; Breukelman AJ; Zwetsloot CP; van der Graaff MM; Wohlgemuth M; Hughes RAC; Cornblath DR; van Doorn PA;
    Lancet Neurol; 2021 Apr; 20(4):275-283. PubMed ID: 33743237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.